The analysis notes that despite a major patent cliff, with Eliquis and Opdivo losing U.S. patent exclusivity in 2028, Bristol Myers Squibb's stock appears cheap at under 10 times forward earnings. Analysts forecast earnings to drop from $6.95 to $6.56 per share next year. However, management has addressed these risks through cost-cutting and acquisitions, positioning the company well in cardiovascular, immunology, and oncology. Coupled with a forward payout ratio of around 40%, the fears of a "yield trap" are considered exaggerated.